Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Insulet Corporation [PODD]
Reports for Purchase
Showing records 241 - 260 ( 344 total )
Company: Insulet Corporation
Industry: Medical - Products
MedTech Stocks To Watch This Week
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MedTech Stocks To Watch This Week
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q4 prereleased below expectations - not as bad as headline; maintain HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Negatively Pre-Announces, But Positive LT-Thesis Remains Intact; Lowering PT to $43; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Some Surprises, But We Stay the Course; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of ~4,800 pump users (2007 - present)
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
International End-User OmniPod Sales Grew 60+% Over the Past 6 Months; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Amgen Showcases OmniPod for Delivery of Neulasta; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Initiating Coverage on Insulin Pump Companies
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
CEO transition, revenue guidance reiterated, maintain HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
OmniPod continues 35% year-over-year growth, guidance trimmed, maintain HOLD
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 4,500+ pump users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Solid First Quarter, Strength To Continue and Drive Profitability by Year End
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Inline Q1 on revs, loss per share above expectations, raise to HOLD from SELL
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 4,000+ pump users (2007 - present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Strong Quarter, Guiding 30% OmniPod Growth in 2014, Partnerships Provide Additional Upside
Provider: The Benchmark Company
Analyst: WALD J
Company: Insulet Corporation
Industry: Medical - Products
Morning Call
Provider: The Benchmark Company
Company: Insulet Corporation
Industry: Medical - Products
Inline Q4 on revs, loss per share above expectations, maintain SELL, PT to $34.50
Provider: FELTL & COMPANY
Analyst: HAYNOR B